NCT05610813已完成3 期
Multicentre, Randomized, Open-label Study to Prove an Additional Benefit of the Full-spectrum Cannabis Extract VER-01 Over Opioids in the Treatment of Patients With Chronic Non-specific Low Back Pain
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 384
- 试验地点
- 2
- 主要终点
- Risk of developing constipation
研究概览
简要总结
Randomized, open-label, parallel-group phase III trial to prove an additional benefit of the full-spectrum cannabis extract VER-01 over opioids in patients with chronic non-specific low back pain for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.
详细描述
The test intervention VER-01 is a cannabis-based pain medication currently under clinical development that is expected to provide adequate pain relief while being better tolerated in long-term treatment compared to opioid analgesics. This study aims to demonstrate the superior tolerability, especially in terms of bowel function, of VER-01 compared to existing authorised and marketed opioid analgesics in patients with chronic non-specific low back pain. In addition, the safety and tolerability as well as the efficacy of VER-01 compared to opioid therapy will be evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female patients ≥18 years of age
- •Provision of informed consent form voluntarily signed and dated by the patient
- •For women of childbearing potential and men of reproductive potential: use of a reliable contraceptive method (Pearl index < 1) at least 1 month before the start of the study and willingness to use it during the study participation and 3 months after the last intake of the test or comparative intervention
- •Patient understands the local language and is willing and able to comply with scheduled visits, treatment plan, patient diary and other study related procedures throughout study participation
- •Chronic (for at least 3 months) non-specific pain in the lower back (between the 12th thoracic vertebra and lower gluteal folds). Non-specific pain refers to pain without a clear specific treatable cause.
- •Patients with indicated drug treatment where previous optimized treatments with non-opioid analgesics (including combinations) have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.
- •Low back pain intensity on average at least 4 points on an 11-point Numeric Rating Scale in the last 4 weeks prior visit 1
- •Ongoing non-drug pain therapy (physical or behavioral therapy) must have been stable for at least 2 weeks prior visit 1 and must be continued during the run-in phase
- •Ongoing additional analgesic treatment prior visit 1 must be continued during the run-in phase
- •Bowel Function Index total score of 28.8 or less at visit 1.
排除标准
- •Patients with a known history of alcohol/drug/medication abuse or dependency and previous or current use of methadone
- •Evidence of drugs of abuse or illegal drugs by urine drug test performed at visit 1
- •Known intolerance or hypersensitivity to ingredients of rescue medication, opioid therapy (assigned by the investigator) and/or VER-01
- •Participation in another clinical interventional study within the last 30 days prior screening visit (visit 1)
- •Occupational groups with primary activity of operating machinery and driving motor vehicles
- •Planned blood donation or planned donation or freezing of sperm or oocytes during study participation and 3 months after end of study participation
- •Pregnant or breastfeeding female patients
- •Patient is unable to provide written informed consent, in need for care, has a guardian/caretaker, is immobile, or is particularly vulnerable (e.g., imprisoned; institutionalised by a court or judicial authority; dependent or employed by the sponsor, an external service provider of the sponsor (involved in the conduct of the study), the investigator or the trial site)
- •Known use of opioid or cannabis-based treatments within 30 days before screening visit (visit 1)
- •Patients for whom cannabis or opioid therapy is not indicated, e.g., due to a history of non-response to opioid therapy or cannabis-based medicines in the treatment of chronic non-specific low back pain in the past.
- •Start of or planned non-drug pain therapy during run-in phase (physical or behavioral therapy)
- •Start or planned start of an additional analgesic treatment during run-in phase
- •Ongoing monoamine oxidase inhibitor therapy at screening visit (visit 1)
- •Patients with history of cancer in the last 5 years prior to screening visit (visit 1). Except for cutaneous basal cell or squamous cell cancer resolved by excision without recurrence and cervical cancer in situ resolved by excision with negative pap test.
- •Painful comorbidities which could interfere with the low back pain intensity assessment during the study
- •Known history of human immunodeficiency virus (HIV) infection
- •Severe forms of the following diseases: Anaemia, haematological / autoimmune / endocrine / renal / hepatic / respiratory / cardiovascular / neurological / gastrointestinal / symptomatic peripheral vascular diseases.
- •Cardiovascular event in the last three months before screening visit (visit 1)
- •Known uncontrolled hypertension (average systolic blood pressure ≥140 mmHg or average diastolic blood pressure
- •≥90 mmHg) and/or untreated hypothyroidism
- •Patients with Crigler-Najjar syndrome, Rotor syndrome and/or porphyria
- •History of major trauma or back surgery in the last 2 months prior to screening visit (visit 1)
- •Known history of or current severe psychiatric illness
- •Known history of or current severe depression (not due to chronic low back pain) (assessed by Patient Health Questionnaire - 9) and/or suicidal ideation (assessed by Columbia-Suicide Severity Rating Scale) at screening visit (visit 1)
- •Patients with severe respiratory depression
- •Patients with lung disease associated with impaired lung function (e.g., acute or severe bronchial asthma or hypercapnia/respiratory failure).
- •Patients with conditions of increased intracranial pressure due to head injury or disease of the brain.
- •Patients with existing or suspected paralytic ileus
- •Patients with intestinal obstruction due to intestinal paralysis
研究组 & 干预措施
Test intervention: VER-01
Experimental
VER-01 will be administered twice daily to patients randomized to treatment arm VER-01.
干预措施: VER-01 (Drug)
Comparative intervention: Opioid therapy (with an authorised and marketed opioid, ATC code N02A)
Active Comparator
Opioids will be administered according to the SmPC to patients randomized to treatment arm opioid therapy.
干预措施: Opioid therapy (Drug)
结局指标
主要结局
Risk of developing constipation
时间窗: 190 days
Number and proportion of constipation responders at the end of treatment phase (Visit 9). A constipation responder is defined as a patient with 1. a change from baseline (visit 2) in Bowel Function Index (BFI) total score of at least 15 points at Visit 9 and 2. a BFI total score of more than 28.8 at Visit 9.
次要结局
- Efficacy based on pain reduction in NE patients(190 days)
- Efficacy based on pain reduction(190 days)
- Efficacy based on pain reduction and interference with sleep(190 days)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic LeukemiaLymphocytic Leukemia, ChronicNCT02242942Hoffmann-La Roche445
已完成
3 期
A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukemiaNCT02005471Hoffmann-La Roche389
已完成
3 期
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAsMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicNCT02907359Astex Pharmaceuticals, Inc.417
尚未招募
3 期
JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins MutationsLocal Advanced or Metastatic NSCLCNCT06380348Shanghai JMT-Bio Inc.398
已完成
3 期
Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis BChronic Hepatitis BNCT00071201Gilead Sciences48